Cancer Immunotherapy Using Checkpoint Inhibitors: Future Directions 3.0

Dear Colleagues, 

This Special Issue is the continuation of our 2019 Special Issue, “Cancer Immunotherapy Using Checkpoint Inhibitors: Future Directions” and 2021 Special Issue “Cancer Immunotherapy Using Checkpoint Inhibitors: Future Directions 2.0”.

Immune checkpoints are regulators of the immune system. Checkpoint inhibitor monoclonal antibodies that block CTLA-4 or PD1/PD-L1 have been approved for the treatment of several cancers including melanoma, bladder, and lung cancer. Despite increases in overall survival, not all patients respond to treatment. Approaches to increase survival include the use of new checkpoint inhibitors to regulate T cell responses and other immune effectors, identification of predictive biomarkers, modulators of the immune response, and the use of combination immunotherapies and therapies. This Special Issue will incorporate, but is not limited to, the following sub-topics:

• Novel checkpoints and inhibitors
• Immune checkpoint activators
• Immune regulation
• Biomarkers predictive of response
• Immunomodulatory agents including cytokines
• Targeting of innate immunity
• Adaptive immunity
• Neoantigen targeted therapies
• T cell exhaustion
• Targeting of immunosuppressive cells
• Mechanisms of tumor immune cell evasion
• Modulation of the immunosuppressive tumor microenvironment
• Targeting Wnt ligand signaling

Prof. Dr. Donald J. Buchsbaum
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.